Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Advanced Renal Cell Carcinoma (RCC): early-phase trial registry

1 of 1 indexed Advanced Renal Cell Carcinoma (RCC) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Advanced Renal Cell Carcinoma (RCC): 1 US clinical trial tracked, 1 recruiting.

Advanced Renal Cell Carcinoma (RCC) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 1 of these trials.

Enrollment posture brief

Registry condition advanced-renal-cell-carcinoma-rcc

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Advanced Renal Cell Carc (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Advanced Renal Cell Carcinoma (RCC)

Advanced Renal Cell Carcinoma (RCC) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Renal Cell Carcinoma (RCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Renal Cell Carcinoma (RCC) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Advanced Renal Cell Carcinoma (RCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cabozantinib Drug
1 trials
Pumitamig Drug
1 trials
Ipilimumab Drug
1 trials
Nivolumab Drug
1 trials

US sites by state

Facility locations filed on Advanced Renal Cell Carcinoma (RCC) trials. A trial with sites in several states counts in each.

Washington 1 trials
Utah 1 trials
South Carolina 1 trials
Ohio 1 trials
New York 1 trials
Missouri 1 trials
Maryland 1 trials
Iowa 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Renal Cell Carcinoma (RCC) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Advanced Renal Cell Carcinoma (RCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Bristol-Myers Squibb sponsors the most Advanced Renal Cell Carcinoma (RCC) trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Renal Cell Carcinoma (RCC) condition card totals 1 registered trials; most-linked intervention Cabozantinib; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.